Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors

Cancers(2022)10.3390/cancers14123015Source: DataRank Database

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.19)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Charles G. Eberhart ORCID,Christine A. Pratilas ORCID,Jaishri O. Blakeley ORCID,Christine Davis ORCID,Marija Stojanova

Live enrichment

PubMed:35740680 PMC:PMC9221513 OpenAlex:https://openalex.org/W4283122595

Pilocytic/Pilomyxoid Fund

Grant: DOD W81XWH-18-1-0496

Pilocytic/Pilomyxoid Fund

Grant: P30 CA006973

Pilocytic/Pilomyxoid Fund

Grant: P50CA211015

United States Department of Defense

Grant: W81XWH-18-1-0496

National Institutes of Health

Grant: 5P50CA211015-02

UCLA SPORE in Brain Cancer

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

FWCI

2.19

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/14/12/3015/pdf?version=1655881511

publisherhttps://www.mdpi.com/2072-6694/14/12/3015/pdf?version=1655881511

publisherhttps://www.mdpi.com/2072-6694/14/12/3015/pdf

journalhttps://doi.org/10.3390/cancers14123015

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35740680

Fields of Study

Glioma Diagnosis and TreatmentNeurofibromatosis and Schwannoma CasesOcular Oncology and Treatments0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicine

Keywords

ATRXTemozolomideCancer researchSynthetic lethalityNeurofibromatosisGliomaTelomereCell cultureDacarbazineNeurofibromatosis type IBiologyMedicineDNA repairMelanomaMutationPathologyDNAGeneticsAlternative lengthening of telomeresArticle

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors

FAIR Checklist

Authors (10)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)